Drugs / EN3835
EN3835
also known as
CCH · Collagenase Clostridium Histolyticum · Collagenase clostridium histolyticum-aaes
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02889848 | Oct 2016 → Oct 2018 | leiomyoma | Advance Biofactures Corporation | Completed | No outcome recorded |
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT05152173 | Nov 2021 → Jan 2023 | plantar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | Missed primary |
| Phase 2 | NCT04496167 | Jul 2020 → Apr 2022 | frozen shoulder | Endo USA Inc., a Keenova Therapeutics Company | Completed | Missed primary |
| Phase 2 | NCT04209530 | Nov 2019 → Jul 2020 | cellulitis, panniculitis | Endo USA Inc., a Keenova Therapeutics Company | Terminated | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06151197 | Nov 2023 → Jun 2026 | plantar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | Met primary |
| Phase 3 | NCT05254457 | Feb 2022 → Mar 2024 | plantar fibromatosis | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT04170296 | Nov 2019 → Oct 2020 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03446781 Comparator | Feb → Sep 2018 | panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EN3835 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02889848 ↗ |
| Known as | CCH | “We tested the hypothesis that injection of a purified form of collagenase Clostridium histolyticum (CCH) that selectively digests type I and type III collagens would alter ECM...” PMID 34323413 ↗ Jul 20212“OBJECTIVE: To assess collagenase clostridium histolyticum-aaes (CCH) for the treatment of cellulite.” PMID 33840781 ↗ May 2021 “Collagenase Clostridium Histolyticum (CCH)” NCT04170296 ↗ |
| Known as | Collagenase Clostridium Histolyticum | “Collagenase Clostridium Histolyticum (CCH)” NCT04170296 ↗ |
| Known as | Collagenase clostridium histolyticum-aaes | “OBJECTIVE: To assess collagenase clostridium histolyticum-aaes (CCH) for the treatment of cellulite.” PMID 33840781 ↗ May 2021 |
| Modality | Protein / enzyme biologic | “purified form of collagenase Clostridium histolyticum (CCH)” PMID 34323413 ↗ Jul 2021 |
| Route | Other | “single injection of study drug” NCT02889848 ↗ |